PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Regulatory News:NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial result.